File Download

There are no files associated with this item.

Supplementary

Conference Paper: Managing Complications of Liver Cirrhosis and Portal Hypertension

TitleManaging Complications of Liver Cirrhosis and Portal Hypertension
Authors
Issue Date2016
PublisherMalaysian Society of Gastroenterology & Hepatology.
Citation
Annual Scientific Congress of Malaysian Society of Gastroenterology & Hepatology (MSGH): GUT 2016, Kuala Lumpur, Malaysia, 22-24 July 2016. In Souvenir Programme and Abstract Book, p. 39 How to Cite?
AbstractIn patients with decompensated cirrhosis, the development of variceal bleeding or hepatorenal syndrome (HRS) is often associated with poor outcome and high mortality rates without liver transplantation. Variceal bleeding occurs at a rate of approximately 5-15% per year in those with established cirrhosis, and treatment comprises of general supportive measures, pharmacological therapy, endoscopic therapy, and rescue therapy for those who have failed pharmacologic and endoscopic therapies. For those with cirrhosis and ascites, the annual in incidence of hepatorenal syndrome (HRS) is an estimated 8%, with a prevalence rate ranging from 13% to 45%. The prognosis is generally poor, with survival usually measured in weeks and months for type 1 and 2 HRS respectively. The pathophysiology of HRS is largely an effect of peripheral vasodilatation, and therefore the primary medical therapy employs the use of vasoconstrictor therapy to improve renal perfusion. The use of albumin increases the effective arterial blood volume, further augmenting the effect of vasoconstrictor therapy. For those that relapse after stopping therapy, re-treatment is often effective, and may be required over a prolonged period as a bridge to liver transplantation. The ultimate treatment for decompensated cirrhosis and HRS is liver transplantation, which significantly improves long-term survival. Therefore, timely referral to a transplant center is essential.
DescriptionLecture 4
Persistent Identifierhttp://hdl.handle.net/10722/235753

 

DC FieldValueLanguage
dc.contributor.authorFung, JYY-
dc.date.accessioned2016-10-17T02:53:00Z-
dc.date.available2016-10-17T02:53:00Z-
dc.date.issued2016-
dc.identifier.citationAnnual Scientific Congress of Malaysian Society of Gastroenterology & Hepatology (MSGH): GUT 2016, Kuala Lumpur, Malaysia, 22-24 July 2016. In Souvenir Programme and Abstract Book, p. 39-
dc.identifier.urihttp://hdl.handle.net/10722/235753-
dc.descriptionLecture 4-
dc.description.abstractIn patients with decompensated cirrhosis, the development of variceal bleeding or hepatorenal syndrome (HRS) is often associated with poor outcome and high mortality rates without liver transplantation. Variceal bleeding occurs at a rate of approximately 5-15% per year in those with established cirrhosis, and treatment comprises of general supportive measures, pharmacological therapy, endoscopic therapy, and rescue therapy for those who have failed pharmacologic and endoscopic therapies. For those with cirrhosis and ascites, the annual in incidence of hepatorenal syndrome (HRS) is an estimated 8%, with a prevalence rate ranging from 13% to 45%. The prognosis is generally poor, with survival usually measured in weeks and months for type 1 and 2 HRS respectively. The pathophysiology of HRS is largely an effect of peripheral vasodilatation, and therefore the primary medical therapy employs the use of vasoconstrictor therapy to improve renal perfusion. The use of albumin increases the effective arterial blood volume, further augmenting the effect of vasoconstrictor therapy. For those that relapse after stopping therapy, re-treatment is often effective, and may be required over a prolonged period as a bridge to liver transplantation. The ultimate treatment for decompensated cirrhosis and HRS is liver transplantation, which significantly improves long-term survival. Therefore, timely referral to a transplant center is essential.-
dc.languageeng-
dc.publisherMalaysian Society of Gastroenterology & Hepatology. -
dc.relation.ispartofMalaysian Society of Gastroenterology and Hepatology Annual Scientific Congress (MSGH): GUT 2016-
dc.titleManaging Complications of Liver Cirrhosis and Portal Hypertension-
dc.typeConference_Paper-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.hkuros260424-
dc.identifier.spage39-
dc.identifier.epage39-
dc.publisher.placeMalaysia-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats